A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy
CIDP
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

BIOLOGICAL: empasiprubart
BIOLOGICAL: IVIg
OTHER: empasiprubart-placebo
OTHER: IVIg-placebo

Sponsor

argenx